Table 1 Uni- and multivariable Cox proportional hazards regression analysis of progression-free (A) and overall (B) survival based on CTC counts, previous and newly defined baseline characteristics.
Univariable | Multivariable | ||||
|---|---|---|---|---|---|
Cox proportional hazard | Cox proportional hazard | ||||
Variable | Categories | HR (95% CI) | Pa | HR (95% CI) | Pa |
(A) PFS | |||||
Age | Continuous | 1.018 (0.993–1.043) | 0.159 | ||
Chemotherapy status | Naïve vs. pretreated | 2.601 (1.729–3.912) | <0.0001 | 2.832 (1.467–5.467) | 0.002 |
Prior ARSi exposure | No vs. yes | 1.715 (1.011–2.909) | 0.045 | 1.030 (0.444–2.388) | 0.945 |
Metastases at start of study | Non-visceral/nodal vs. visceral | 2.402 (1.459–3.953) | 0.001 | 0.938 (0.478–1.842) | 0.852 |
Baseline PSA | Continuous | 1.002 (1.001–1.002) | <0.0001 | 1.001 (1.000–1.002) | 0.018 |
Baseline LDH | Continuous | 1.001 (1.001–1.002) | <0.0001 | 1.000 (1.000–1.001) | 0.528 |
Baseline CTC (/7.5 mL) | Continuous | 1.003 (1.002–1.005) | <0.0001 | 1.003 (1.002–1.004) | <0.0001 |
Baseline SI | Continuous | 1.918 (1.196–3.075) | 0.007 | 1.701 (0.812–3.563) | 0.159 |
(B) OS | |||||
Age | Continuous | 1.008 (0.971–1.048) | 0.671 | ||
Chemotherapy status | Naïve vs. pretreated | 3.567 (1.875–6.786) | 0.0001 | 3.372 (1.532–7.423) | 0.003 |
Prior ARSi exposure | No vs. yes | 1.853 (0.884–3.884) | 0.102 | ||
Metastases at start of study | Non-visceral/nodal vs. visceral | 2.879 (1.509–5.493) | 0.001 | 1.657 (0.741–3.704) | 0.219 |
Baseline PSA | Continuous | 1.002 (1.001–1.003) | <0.0001 | 1.002 (1.000–1.003) | 0.009 |
Baseline LDH | Continuous | 1.001 (1.0004–1.002) | 0.001 | 0.999 (0.997–1.000) | 0.053 |
Baseline CTC (/7.5 mL) | Continuous | 1.003 (1.002–1.004) | <0.0001 | 1.006 (1.002–1.010) | 0.003 |
Baseline SI | Continuous | 3.034 (1.479–6.228) | 0.002 | 1.901 (0.748–4.830) | 0.177 |
